TZ 101

Drug Profile

TZ 101

Alternative Names: ASC-101; Ftv1+Gdp-Fucose; GDP-fucose protein O-fucosyltransferase 1 - Targazyme; Peptide-O-fucosyltransferase - Targazyme; TZ101

Latest Information Update: 08 Mar 2017

Price : $50

At a glance

  • Originator America Stem Cell
  • Developer America Stem Cell; Indiana University School of Medicine; Oregon Health & Science University; Targazyme; University of California, San Diego; University of Texas M. D. Anderson Cancer Center; Wake Forest University School of Medicine
  • Class Fucosyltransferases; Hexosyltransferases
  • Mechanism of Action Fucosyltransferase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease; Haematological malignancies
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Graft-versus-host disease; Haematological malignancies
  • Preclinical Diabetic retinopathy; Leukaemia; Multiple myeloma; Muscle injury
  • No development reported Multiple sclerosis; Myelodysplastic syndromes; Myocardial infarction; Peripheral ischaemia; Stomatitis
  • Discontinued Autoimmune disorders; Bone metastases; Stroke

Most Recent Events

  • 06 Mar 2017 The US FDA grants an IND clearance to initiate a phase II trial in Haematological malignancies (In children)
  • 18 Jan 2017 Targazyme has patent protection for Fucosylation technology platform in USA
  • 18 Jan 2017 Targazyme has patent protection or patents pending for Fucosylation technology platform in Europe, Japan, Australia, Korea, India, China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top